Ionis Pharmaceuticals, Inc. (IONS)
62.03
+2.29
(+3.83%)
USD |
NASDAQ |
Aug 24, 16:00
61.98
-0.05
(-0.08%)
After-Hours: 20:00
Ionis Pharmaceuticals Enterprise Value : 10.03B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 10.03B |
| August 20, 2026 | 9.867B |
| August 19, 2026 | 10.21B |
| August 18, 2026 | 10.01B |
| August 17, 2026 | 9.846B |
| August 14, 2026 | 9.615B |
| August 13, 2026 | 9.389B |
| August 12, 2026 | 9.498B |
| August 11, 2026 | 9.314B |
| August 10, 2026 | 9.566B |
| August 07, 2026 | 9.503B |
| August 06, 2026 | 9.160B |
| August 05, 2026 | 9.110B |
| August 04, 2026 | 9.256B |
| August 03, 2026 | 9.160B |
| July 31, 2026 | 8.709B |
| July 30, 2026 | 8.960B |
| July 29, 2026 | 9.085B |
| July 28, 2026 | 9.294B |
| July 27, 2026 | 9.403B |
| July 24, 2026 | 9.501B |
| July 23, 2026 | 9.389B |
| July 22, 2026 | 9.080B |
| July 21, 2026 | 8.978B |
| July 20, 2026 | 8.905B |
| Date | Value |
|---|---|
| July 17, 2026 | 9.143B |
| July 16, 2026 | 9.186B |
| July 15, 2026 | 9.200B |
| July 14, 2026 | 9.233B |
| July 13, 2026 | 9.534B |
| July 10, 2026 | 9.783B |
| July 09, 2026 | 10.78B |
| July 08, 2026 | 14.12B |
| July 07, 2026 | 14.43B |
| July 06, 2026 | 13.91B |
| July 02, 2026 | 13.68B |
| July 01, 2026 | 13.25B |
| June 30, 2026 | 13.27B |
| June 29, 2026 | 14.02B |
| June 26, 2026 | 14.10B |
| June 25, 2026 | 13.63B |
| June 24, 2026 | 13.33B |
| June 23, 2026 | 13.24B |
| June 22, 2026 | 13.22B |
| June 18, 2026 | 12.93B |
| June 17, 2026 | 12.96B |
| June 16, 2026 | 12.76B |
| June 15, 2026 | 12.90B |
| June 12, 2026 | 12.79B |
| June 11, 2026 | 12.88B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Biogen, Inc. | 39.09B |
| BridgeBio Pharma, Inc. | 18.61B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -114.65M |
| Revenue (Quarterly) | 267.95M |
| Total Expenses (Quarterly) | 382.60M |
| EPS Diluted (Quarterly) | -0.6931 |
| Gross Profit Margin (Quarterly) | 96.13% |
| Profit Margin (Quarterly) | -42.79% |
| Earnings Yield | -5.60% |
| Normalized Earnings Yield | -5.901 |